Plus Therapeutics reports 2024 net loss of $13.0M, cash $3.6M; raised $15M in private placement

PLUS THERAPEUTICS, INC.

Cash and investments $3.6M at Dec 31, 2024 vs $8.6M at Dec 31, 2023.
Net loss $13.0M ($1.95 per share) in 2024 vs $13.3M ($4.24 per share) in 2023; operating loss $14.7M.
Raised $15.0M via private placement, regains Nasdaq compliance and extends runway into 2026.
FDA agreed on brand name REYOBIQ; orphan drug designation for leptomeningeal metastases in lung cancer.
Appointed Dr. Michael Rosol as Chief Development Officer; Russell Bradley as President/GM of CNSide Diagnostics.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0000950170-25-046110
form_type: 8-K
ticker: PSTV
cik: 0001095981
company_name: PLUS THERAPEUTICS, INC.
filed_at: 2025-03-27T23:59:59+00:00
discovered_at: 2026-05-14T18:03:02.919558+00:00
generated_at: 2026-05-24T03:38:46.126924+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.55
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0000950170-25-046110
json_url: https://secwatch.observer/filing/0000950170-25-046110.json
markdown_url: https://secwatch.observer/filing/0000950170-25-046110.md
text_url: https://secwatch.observer/filing/0000950170-25-046110.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1095981/000095017025046110/0000950170-25-046110-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1095981/000095017025046110/pstv-20250327.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0000950170-25-046110

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.